Drug Discovery World

FEBRUARY 15, 2023

Further studies elucidating the role of tumour microenvironment and its immunosuppressive elements including tumour associated macrophages have shown encouraging results in improving the efficacy of IO therapies. Over 250 clinical trials are currently in progress, and novel immuno-oncological treatments are already proving to be successful.

Research 52

Research In-Vitro In-Vivo Development 52

Drug Discovery World

NOVEMBER 30, 2023

GSK has developed high-throughput mammalian and E. coli expression systems and is using high-throughput expression pipelines to screen constructs for optimal expression to generate protein and cellular reagents. DDW’s Megan Thomas attended PEGS Europe 2023 in Lisbon, Portugal, from Tuesday 14 November to Thursday 16 November 2023.

Antibody 59

Antibody Protein Engineer In-Vivo 59

Drug Discovery World

DECEMBER 13, 2023

In the ever-evolving landscape of therapeutic development, the role of antibodies has become increasingly apparent. Moreover, custom antibodies are a key reagent in companion diagnostics for these novel therapeutics. This article is sponsored by Fortis Life Sciences.

Life Science 59

Life Science Antibody Manufacturing In-Vivo 59

The Pharma Data

OCTOBER 14, 2020

Priothera will use the funds to progress the clinical development of mocravimod, a modulator of sphingosine 1 phosphate (S1P) receptors, to enhance the curative potential of allogeneic hematopoietic stem cell transplantation (HSCT) for treating AML. All jobs have been maintained and the workforce has grown from about 220 to 350.

Clinical Trials 52

Clinical Trials Clinical Trials Manufacturing Trials 52